End-of-day quote
INDONESIA S.E.
06:00:00 2024-05-30 pm EDT
5-day change
1st Jan Change
1,490
IDR
-1.97%
-4.49%
-7.45%
Sales 2024 *
32,560B
2.02B
Sales 2025 *
34,951B
2.17B
Capitalization
68,921B
4.27B
Net income 2024 *
3,132B
194M
Net income 2025 *
3,496B
217M
EV / Sales 2024 *
2
x
Net cash position
2024
*
3,714B
230M
Net cash position
2025
*
4,587B
284M
EV / Sales 2025 *
1.84
x P/E ratio 2024 *
22
x
P/E ratio 2025 *
19.8
x
Employees
13,062
Yield 2024 *
2.21%
Yield 2025 *
2.32%
Free-Float
40.44%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Nomura Adjusts Kalbe Farma’s Price Target to 1,900 Rupiahs From 1,850 Rupiahs, Keeps at Buy
May. 17
MT
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 30
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 01
CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy
Feb. 20
MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-06
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-28
CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR2,500 From IDR2,250, Keeps at Buy
23-01-30
MT
Progen Co. Ltd. announced that it has received IDR 155.72 billion in funding from PT Kalbe Farma Tbk.
23-01-01
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-30
CI
PT Kalbe Farma Tbk. completed the acquisition of a 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S.
22-10-25
CI
Nomura Adjusts Kalbe Farma's Price Target to 2,250 Rupiahs From 1,905 Rupiahs, Keeps at Buy
22-09-22
MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2022
22-07-28
CI
PT Kalbe Farma Tbk. entered into agreement to acquire 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S.
22-07-24
CI
More news
Nomura Adjusts Kalbe Farma’s Price Target to 1,900 Rupiahs From 1,850 Rupiahs, Keeps at Buy
May. 17
MT
Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy
Feb. 20
MT
Nomura Adjusts Kalbe Farma’s Price Target to IDR2,500 From IDR2,250, Keeps at Buy
23-01-30
MT
Nomura Adjusts Kalbe Farma's Price Target to 2,250 Rupiahs From 1,905 Rupiahs, Keeps at Buy
22-09-22
MT
Nomura Adjusts Kalbe Farma's Price Target to 1,905 Indonesian Rupiahs From1,550 Indonesian Rupiahs, Keeps at Buy
22-01-11
MT
More recommendations
1 day -1.97%
1 week -4.49%
1 month +2.41%
6 months -10.51%
Current year -7.45%
More quotes
Managers
Title Age Since
Chief Executive Officer
59
96-12-31
Chairman
62
97-02-28
Chief Tech/Sci/R&D Officer
-
-
Members of the board
Title Age Since
Director/Board Member
60
99-12-31
Chairman
62
97-02-28
Director/Board Member
52
14-12-31
More insiders
Date
Price
Change
Volume
24-05-31
1,490
-1.97%
117,693,500
24-05-30
1,520
+0.33%
30,139,500
24-05-29
1,515
-2.26%
29,138,000
24-05-28
1,550
-0.96%
27,878,800
End-of-day quote
INDONESIA S.E., May 30, 2024
More quotes
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
More about the company
Last Close Price
1,490
IDR
Average target price
1,761
IDR
Spread / Average Target
+18.21%
Consensus
1st Jan change
Capi.
-7.45% 4.24B +40.73% 739B +32.83% 598B -6.30% 353B +15.15% 318B +4.05% 285B +15.00% 240B -5.52% 206B +6.17% 164B -0.45% 162B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1